Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
The Asia Pacific Cardiovascular Research (ASPIRE) Network
Author(s): Clement Lau , Philip D Adamson , Nicholas Chew , et al Added: 4 months ago

Demographic

Guidelines & Statements
AHA 23 Late-Breaker Discussion: The ARIES HM3 Clinical Trial
Author(s): Harriette Van Spall , Mandeep Mehra Added: 2 years ago
AHA 23 - Investigator, Dr Mandeep R Mehra (Brigham and Women's Hospital and Harvard Medical School, US) is joined by Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the ARIES HM3 trial.ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were… View more

Heart Failure

Electrophysiology & Arrhythmia
Transforming Outcomes with Lipid Clinics in Malaysia: Enablers and Barriers for the Implementation of Multidisciplinary Approach Clinics for the Management of Dyslipidaemia
Author(s): Azhari Rosman , Ahmad Khairuddin Mohamed Yusof , Hafidz Abd Hadi , et al Added: 4 weeks ago

Prevention & Chronic Conditions
TCT 25: Seven-Year Follow-up of the PARTNER 3 Trial
Author(s): Michael J Mack Added: 2 months ago
TCT 2025 - Long-term follow-up of the PARTNER 3 trial showed no safety concerns for transcatheter aortic-valve replacement (TAVR) compared to surgical treatment of aortic stenosis (AS).Dr Michael Mack (Baylor Scott & White Heart Hospital, Plano, US) joins us to share the clinical and echocardiographic outcomes from the seven-year follow-up of the PARTNER 3 low-risk randomised trial (NCT02675114)… View more

Imaging & Diagnostics

Intervention
AHA 25: Lp(a) and ASCVD: Translating Causal Evidence into Clinical Practice
Author(s): Michelle O'Donoghue Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) joins us to discuss the evolving understanding of the causal relationship between elevated lipoprotein(a) and atherosclerotic cardiovascular disease, and what this means for risk stratification and management strategies in clinical practice.Dr O'Donoghue begins by highlighting the importance for clinicians to… View more

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
AHA 25: The OCEAN Trial
Author(s): Atul Verma Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Atul Verma (McGill University Health Centre, Montreal, CA) joins us to share outcomes from OCEAN (NCT02168829). The prospective, open-label, randomised trial aimed to investigate ongoing oral anticoagulation with rivaroxaban 15 mg daily compared to antiplatelet therapy in patients with clinical stroke risk factors at least one year post-successful catheter… View more

Anticoagulation

Electrophysiology & Arrhythmia
2 Trials That Will Change My Practice with Prof Rasha Al-Lamee
Author(s): Rasha Al-Lamee Added: 2 months ago
TCT 2025 - In this comprehensive highlights video from TCT 2025, Prof Rasha Al-Lamee (Imperial College Healthcare NHS Trust, UK) delivers an expert analysis of the groundbreaking late-breaking trials that are set to reshape interventional cardiology practice.Join Prof Al-Lamee as she breaks down the pivotal studies driving innovation in cardiovascular care and discusses their implications for… View more

Intervention
TCT 25: 5 Trials That Will Change My Practice with Dr Mirvat Alasnag
Author(s): Mirvat Alasnag Added: 2 months ago
TCT 2025 - In this insightful highlights video from TCT 2025, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, SA) provides expert commentary on the most impactful late-breaking clinical trials presented at this year's conference.The commentary distills the most important late-breaking trials in structural cardiology, coronary interventions, and artificial intelligence presented at TCT 2025… View more

Digital Health

Guidelines & Statements
Clinical Features and the Efficacy of Thrombolytic Therapy in de Winter
Author(s): Nirmalatiban Parthiban , Fiona Boland , Huzairi Sani Added: 9 months ago

Prevention & Chronic Conditions

MI/ACS
ADA 25: Clinical Implications of STRIDE for Endocrinologists
Author(s): Added: 6 months ago
ADA 2025 - We are joined by Dr Alice Cheng (University of Toronto, Toronto, CA) to discuss the clinical implications of STRIDE (NCT04560998). The placebo-controlled study investigated whether semaglutide with standard-of-care treatment has an effect on walking ability in patients with PAD and T2D. The primary outcome measure was the change in maximum walking distance on a constant load treadmill… View more

Cardiovascular Renal Metabolic

Vascular Disease and Surgery